Polifarma İlaç Continues to Carry Out R&D Projects

For 36 years contributing to public health and the healthcare sector in Türkiye, Polifarma, a 100% domestically-owned pharmaceutical company, has achieved recognition as the 4th company running the most projects in Türkiye's pharmaceutical sector. Polifarma Pharmaceuticals ranked among the 'Top 10 Companies Running the Most Projects' across all sectors in the 9th edition of the 'Companies Running the Most Projects in R&D Centers' research conducted by Turkishtime, an economics and business portal, last week.

Exports to 70 countries continue

In the 'Companies Running the Most Projects in the Pharmaceutical Sector' list published following the research, Polifarma ranked 4th, further demonstrating its R&D strength through this survey. 100% Turkish-owned and exporting to 70 countries, Polifarma continues working for the health of both Türkiye and the world in its PolAr-Ge center. Polifarma also ranked in the top 50 in the same research in the 'Number of Female Employees Working in R&D Centers' category across all sectors, based on the number of female employees working in its PolAr-Ge center.

Polifarma concentrated its R&D work on original molecules

Recently, through R&D investments and ongoing projects, Polifarma has begun working on original molecules and achieving results, now aiming to break the belief that original molecules cannot be created in Türkiye. Through active pharmaceutical ingredients production and original work in the near future, it will raise its profile further in both Türkiye and the world.       About The journey of Polifarma, Türkiye's most preferred company in hospital products, began when the late Pharmacist Necdet Nuri Kumrulu became a partner in Aroma Pharmaceuticals, founded in 1963, in 1983. Having acquired the company in 1992, it continued its operations under the same name. Today, as a 100% domestically-owned pharmaceutical company with a 36-year history, it is a market leader in serum production while rapidly developing its IV (intravenous) pharmaceutical portfolio. Since 2021, it continues to grow in prescription markets it has entered.